November 22, 2016 - By Winifred Garcia · 0 Comments
The stock of Zafgen Incorporated (NASDAQ:ZFGN) registered a decrease of 8.1% in short interest. ZFGN’s total short interest was 1.62M shares in November as published by FINRA. Its down 8.1% from 1.77M shares, reported previously. With 335,700 shares average volume, it will take short sellers 5 days to cover their ZFGN’s short positions. The short interest to Zafgen Incorporated’s float is 7.31%. The stock closed at $3.51 during the last session. It is down 48.53% since April 20, 2016 and is downtrending. It has underperformed by 53.09% the S&P500.
Zafgen, Inc. is a biopharmaceutical company. The company has a market cap of $98.69 million. The Firm is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. It currently has negative earnings. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.
Out of 8 analysts covering Zafgen Inc (NASDAQ:ZFGN), 1 rate it a “Buy”, 0 “Sell”, while 7 “Hold”. This means 13% are positive. Zafgen Inc has been the topic of 16 analyst reports since August 25, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating given on Friday, November 13 by Canaccord Genuity. On Thursday, March 10 the stock rating was downgraded by Canaccord Genuity to “Hold”. As per Tuesday, August 25, the company rating was maintained by Cowen & Co. The stock of Zafgen Inc (NASDAQ:ZFGN) earned “Neutral” rating by Suntrust Robinson on Thursday, December 3. The stock of Zafgen Inc (NASDAQ:ZFGN) earned “Buy” rating by SunTrust on Monday, October 19. The rating was downgraded by Cowen & Co on Wednesday, July 20 to “Market Perform”. As per Monday, October 19, the company rating was downgraded by JMP Securities. As per Thursday, December 3, the company rating was downgraded by SunTrust. FBR Capital upgraded it to “Outperform” rating and $20 target price in Thursday, January 21 report. The rating was maintained by FBR Capital on Thursday, October 15 with “Outperform”.
Zafgen, Inc., incorporated on November 22, 2005, is a biopharmaceutical company. The Firm is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity. Beloranib is in Phase III stage of development for PWS. It is also developing ZGN-839, a liver-targeted methionine aminopeptidase 2 (MetAP2) inhibitor, for the treatment of nonalcoholic steatohepatitis (NASH) and abdominal obesity, as well as other second-generation MetAP2 inhibitors for the treatment of severe obesity.
More notable recent Zafgen Inc (NASDAQ:ZFGN) news were published by: Marketwatch.com which released: “Zafgen shares drop more than 40% as drug focus shifted” on July 19, 2016, also Wsj.com with their article: “Zafgen’s Halted Obesity Treatment Shows Effectiveness” published on January 20, 2016, Reuters.com published: “Zafgen to scrap lead obesity drug, shares slide” on July 19, 2016. More interesting news about Zafgen Inc (NASDAQ:ZFGN) were released by: Seekingalpha.com and their article: “Zafgen: Too Cheap To Ignore” published on August 26, 2016 as well as Prnewswire.com‘s news article titled: “Zafgen, Inc. and Its CEO Sued for Securities Fraud” with publication date: October 21, 2015.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Winifred Garcia